[Lab] split one vial across Medutest and Janoshik — 98.3% and 98.7%
Numbers in the title, numbers in the post. split one vial across Medutest and Janoshik — 98.3% and 98.7%.
Since the title puts numbers in the shop window: 98.3% and 98.7%.
Sulphur burps for the first eight days after each step, then nothing. Predictable enough that I planned my week around it.
Came off sema and onto tirz with a two-week gap. The first month was flat and I assumed I had made a mistake. Month two it moved.
Would rather be corrected in public than confident in private.
best — the order this archive was captured in
Research-use-only material is not approved for human use. Anything in this thread about how a research vial "should" titrate is a discussion about chemistry, not a plan.
What step are you on and how long have you been there?
What is the waist doing? That is usually the number still moving during a scale stall.
The thing nobody warned me about was how much of this is logistics — storing it, remembering it, the same day every week.
It is a dual GIP and GLP-1 receptor agonist, and the GIP arm is the part that has no equivalent in the semaglutide threads. That is why the side-effect profile reads differently rather than just milder.
The four-week interval in the label is a minimum. Nothing about the pharmacology requires you to step on schedule, and the trials stepped on a calendar because trials have to.
Which week did the appetite change actually land for you?
[deleted]
Did you come to this from sema, and if so how long was the gap?
pens and vials are the same molecule, the price is the difference
if 7.5 is working, 10 is not automatically better
SURMOUNT-1 landed around 21% at 72 weeks on the top arm
2.5mg is a four-week starting dose, not a maintenance dose. Worth being precise since people search these threads.
Agreed, and the trial number is a mean of a very wide distribution — the tails are enormous and nobody posts from the middle.
Appetite effect for me is flat across seven days. On sema it was a wave. Same person, different molecule.
hold the dose that works, the ladder is not a leaderboard
SURMOUNT-1 ran 72 weeks with the top arm around 21% mean body weight change. SURPASS is the diabetes programme and reports glycaemic endpoints, so quoting the two interchangeably is a category error.
Small fix: SURMOUNT is the obesity programme, SURPASS is the type-2 programme. They are different endpoints and the numbers do not transfer.
Agree. The GIP component is the interesting half and it barely gets discussed outside c/glp1science.
Right. And the sema-to-tirz "conversion" people post is invented. There is no published equivalence.
Have you held a step for longer than the four-week minimum at any point?
Yes. I stepped to 12.5 because the calendar said so, not because anything needed fixing, and I regretted it for a fortnight.
the appetite effect is blunter than sema, in a good way, most weeks
Vials and pens carry the same molecule; what differs is fill volume, device tolerance and whether you are doing your own arithmetic. Neither is inherently more accurate.
the trials titrated on a calendar, real people titrate on symptoms
13kg over 61 weeks, never went past 10mg, and muscle cramps stayed mild the whole way. Posting because the loud threads are all 15mg.
Weekly dosing again, half-life in the same neighbourhood as sema, so a step change takes about a month to reach steady state. Judging a new step at day five is judging noise.
stepping every four weeks is a ceiling on speed, not a schedule you must hit
the four-week step schedule is the label, not folklore
switching from sema is not a dose conversion, there is no clean equivalence
- 1What is the waist doing? That is usually the number still moving during a…14 comments in this branch · started by u/elin_varga